AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Kiora Pharmaceuticals: Navigating Retinal Diseases with KIO-301 and KIO-104
ByAinvest
Tuesday, Nov 4, 2025 5:53 am ET1min read
Kiora Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for retinal diseases. Its two drug candidates, KIO-301 and KIO-104, are under clinical development. KIO-301 aims to restore visual function in patients with retinitis pigmentosa by targeting surviving cells in the retina. A phase 2 trial, ABACUS-2, is underway to investigate the safety, tolerability, and efficacy of up to 3 doses of KIO-301 administered by IVT injection bilaterally every 6 weeks. KIO-104 is being developed for the treatment of diabetic macular edema and is currently in a phase 1 trial.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet